39 results on '"Kerbel, Robert S."'
Search Results
2. Vessel co‐option is common in human lung metastases and mediates resistance to anti‐angiogenic therapy in preclinical lung metastasis models
3. GASTROINTESTINAL CANCER: Rationale for metronomic chemotherapy in phase III trials
4. Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2
5. Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy
6. Drug rechallenge and treatment beyond progression—implications for drug resistance
7. Development and characterization of a clinically relevant mouse model of melanoma brain metastasis
8. Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1
9. Antitumor effects of combining metronomic chemotherapy with the antivascular action of ultrasound stimulated microbubbles
10. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models
11. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
12. Cancer: Chemotherapy counteracted
13. Tumor Angiogenesis
14. Tumor Angiogenesis
15. Five Years of Clinical Experience with Metronomic Chemotherapy: Achievements and Perspectives
16. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing
17. Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors
18. On the Origin and Nature of Elevated Levels of Circulating Endothelial Cells After Treatment With a Vascular Disrupting Agent
19. Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
20. Circulating Endothelial Progenitor Cells
21. Angiogenesis as a therapeutic target
22. Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity
23. Vasohibin: the feedback on a new inhibitor of angiogenesis
24. Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase
25. Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor
26. Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
27. Clinical Trials of Antiangiogenic Drugs: Opportunities, Problems, and Assessment of Initial Results
28. Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches
29. Lineage-specific mechanism of drug and radiation resistance in melanoma mediated by myrosinase-related Protein 2
30. Oncogenes and Angiogenesis: Signaling Three-Dimensional Tumor Growth
31. Activated ras Prevents Downregulation of Bcl-XL Triggered by Detachment from the Extracellular Matrix: A Mechanism of ras-induced Resistance to Anoikis in Intestinal Epithelial Cells
32. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
33. Monoclonal antibodies in cancer therapy: An overview
34. E-Cadherin-dependent Growth Suppression is Mediated by the Cyclin-dependent Kinase Inhibitor p27KIP1
35. The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor
36. Rodent Tumor Models for Anti-cancer Drug Testing: An Overview
37. What is the optimal rodent model for anti-tumor drug testing?
38. A cancer therapy resistant to resistance
39. Cytokines, growth factors and the loss of negative growth controls in the progression of human cutaneous malignant melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.